Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a placenta patch improve C-Section scar healing?

NCT ID NCT07241013

Disease control Sponsor: Asfendiyarov Kazakh National Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new biodegradable patch made from amniotic membrane and calcium alginate to help surgical wounds heal after a C-section. The patch is placed on the skin incision to promote faster healing and better scar quality. Researchers will enroll 100 women and measure healing through blood tests, ultrasound, and scar assessments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tissue-engineered construct made from amniotic membrane and calcium alginate
What this could lead to
If it works, this could offer a safe, natural way to improve wound healing and reduce scarring after C-sections.
What could go wrong
This is an early-stage trial with no phase designation, so results are uncertain. The patch may not improve healing or scar quality more than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women aged 18 years and older. 2. Planned elective cesarean section for medical indications (breech presentation, multiple pregnancy, large fetus, uterine scar, etc.). 3. Absence of severe obstetric complications (e.g., preeclampsia, hemorrhage, placental abruption). 4. No decompensated chronic diseases or acute infections. 5. Signed written informed consent. Exclusion Criteria: 1. Acute infectious, autoimmune, or oncological diseases. 2. Severe pregnancy complications (preeclampsia, eclampsia, decompensated gestational diabetes). 3. Emergency cesarean section. 4. Severe postpartum complications: massive bleeding (\>1000 mL), infection, abscess, severe anemia, allergic reactions to dressing materials. 5. Withdrawal of consent or inability to continue participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cesarean section scar healing are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cesarean section scar healing Skin wound healing after cesarean section

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Perinatology and Pediatric Surgery (ЦПиДКХ)

    RECRUITING

    Almaty, Kazakhstan